Biological Information | |
---|---|
Background Information: | DRAK2, also known as Serine/Threonine Kinase 17b, enables ATP binding activity and protein serine/threonine kinase activity. It involves in intracellular signal transduction and positive regulation of fibroblast apoptotic process. [provided by Alliance of Genome Resources, Apr 2022] |
Target Class: | Kinase |
Accession Number: | NM_004226.4 |
Target Name: | DRAK2 |
Target Aliases: | STK17B, Serine/Threonine Kinase 17b, Death-Associated Protein Kinase-Related 2, Serine/Threonine Kinase 17b (Apoptosis-Inducing) |
Target Species: | Human |
Usage | |
Product Type: | Enzymes |
Application: | Drug Discovery & Development |
Storage Conditions: | 1 year at -70°C |
Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
DRAK2, active
active DRAK2. N-terminal 6His-tagged, recombinant, full length, human DRAK2.
Datasheets
16-003x Datasheet
View Document